ChromaDex (NASDAQ:CDXC) Given New $8.00 Price Target at HC Wainwright

ChromaDex (NASDAQ:CDXC) had its target price hoisted by research analysts at HC Wainwright from $6.00 to $8.00 in a research note issued to investors on Monday, November 27th, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 32.01% from the stock’s previous close.

CDXC has been the subject of several other research reports. Zacks Investment Research cut ChromaDex from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 15th. ValuEngine raised ChromaDex from a “sell” rating to a “hold” rating in a report on Friday, September 8th. Finally, Ladenburg Thalmann Financial Services started coverage on ChromaDex in a report on Monday, September 25th. They issued a “buy” rating and a $7.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. ChromaDex presently has an average rating of “Hold” and an average price target of $7.13.

ChromaDex (NASDAQ CDXC) opened at $6.06 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 4.12. ChromaDex has a twelve month low of $2.26 and a twelve month high of $7.24.

In other ChromaDex news, major shareholder River Ventures Ltd Champion purchased 731,707 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $2,999,998.70. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 11.59% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. bought a new stake in ChromaDex during the 3rd quarter worth approximately $128,000. Bank of Montreal Can bought a new position in shares of ChromaDex in the 2nd quarter worth $168,000. LMR Partners LLP bought a new position in shares of ChromaDex in the 2nd quarter worth $347,000. Goldman Sachs Group Inc. boosted its position in shares of ChromaDex by 870.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares during the last quarter. Finally, Granite Investment Partners LLC boosted its position in shares of ChromaDex by 5.7% in the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after purchasing an additional 13,599 shares during the last quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at

About ChromaDex

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply